EASL Position Paper Classifies Preclinical Models for Steatotic Liver Disease Research

EASL position paper critically reviews and classifies in vivo, in vitro, and ex vivo experimental models for steatotic liver disease (SLD/MASLD/ALD), proposing selection criteria covering hepatic metabolism, histopathology, immunopathology, and multi-organ crosstalk to standardi…

• Guideline/position paper (not a primary study); no patient cohort or diagnostic-accuracy data — no numerical results reported. Covers the full SLD spectrum: MASLD (formerly NAFLD), MetALD, ALD, drug-induced, monogenic, and cryptogenic subtypes.
• Key output: proposed criteria for model selection across SLD subtypes encompassing systemic/hepatic metabolism, cardiometabolic comorbidities, histopathology, immunopathology, and molecular disease-stage features, plus a call for consistent nomenclature harmonized with updated clinical definitions.
• Radiology relevance is indirect: improved preclinical model standardization may accelerate therapeutic pipelines whose endpoints rely on liver imaging biomarkers (steatosis grading, fibrosis staging, HCC detection); the paper itself is hepatology-focused with no imaging methodology content.

RadPigeon summaries are original and for information only. They are not clinical advice.